Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 106 (11), 1970-5

A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline Versus Triple Therapy for the Eradication of Helicobacter Pylori

Affiliations
Randomized Controlled Trial

A Randomized Study Comparing Levofloxacin, Omeprazole, Nitazoxanide, and Doxycycline Versus Triple Therapy for the Eradication of Helicobacter Pylori

P Patrick Basu et al. Am J Gastroenterol.

Abstract

Objectives: Resistance to standard Helicobacter pylori (HP) treatment regimens has led to unsatisfactory cure rates in HP-infected patients. This study was designed to evaluate a novel four-drug regimen (three antibiotics and a proton pump inhibitor (PPI)) for eradication of HP infection in treatment-naive patients.

Methods: Patients with a diagnosis of HP gastritis or peptic ulcer disease confirmed using endoscopy and stool antigen testing were eligible for inclusion in this study. All patients underwent a washout period of 6 weeks from any prior antibiotic or PPI usage. Patients were then randomized to either levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) therapy for 7 days (LOAD-7) or 10 days (LOAD-10), including levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina) 500 mg twice daily with meals and doxycycline 100 mg at dinner, or lansoprozole, amoxicillin, and clarithromycin (LAC) therapy for 10 days, which included lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner. HP eradication was confirmed by stool antigen testing at least 4 weeks after cessation of therapy.

Results: Intention-to-treat analysis revealed significant differences (P<0.05) in the respective eradication rates of the LOAD therapies (88.9% (80/90) LOAD-10, 90% (81/90) LOAD-7, 89.4% (161/180) for combined LOAD) compared with those receiving LAC, 73.3% (66/90). There were no differences in adverse effects between the groups.

Conclusions: This open-label, prospective trial demonstrates that LOAD is a highly active regimen for the treatment of HP in treatment-naive patients. A large randomized controlled trial is warranted to further evaluate the efficacy of this regimen.

Figures

Figure 1
Figure 1
Comparative efficacy, intent-to-treat analysis. *LAC vs. all LOAD, P=0.0001; LAC vs. LOAD-7, P=0.006; LAC vs. LOAD-10, P=0.013. There was no difference between the LOAD regimens as compared with each other. LAC, lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner; LOAD, levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina®) 500 mg twice daily with meals and doxycycline 100 mg at dinner.
Figure 2
Figure 2
Comparative efficacy, per protocol analysis. *LAC vs. all LOAD, P=0.0003; LAC vs. LOAD-7, P=0.0047; LAC vs. LOAD-10, P=0.0035. There was no difference between the LOAD regimens as compared with each other. LAC, lansoprozole 30 mg, amoxicillin 1 g with breakfast and dinner, and clarithromycin 500 mg with breakfast and dinner; LOAD, levofloxacin 250 mg with breakfast, omeprazole 40 mg before breakfast, nitazoxanide (Alina®) 500 mg twice daily with meals, and doxycycline 100 mg at dinner

Comment in

Similar articles

See all similar articles

Cited by 27 PubMed Central articles

See all "Cited by" articles

References

    1. de Vries AC, Kuipers EJ. Helicobacter pylori infection and nonmalignant diseases. Helicobacter. 2010;15 (Suppl 1:29–33. - PubMed
    1. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among H. pylori-infected persons, United States. Emerg Infect Dis. 2004;10:1088–1094. - PMC - PubMed
    1. Houghton JM, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 2005;128:1567–1578. - PubMed
    1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102:1808–1825. - PubMed
    1. Egan BJ, Marzio L, O'Connor H, et al. Treatment of Helicobacter pylori infection. Helicobacter. 2008;13 (Suppl 1:35–40. - PubMed

Publication types

MeSH terms

Feedback